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Purpose or Objective: Based on poor results using 
hypofractionated adjuvant radiotherapy (RT) of early breast 
cancer (BC) 50 Gy/25 fr. has been Danish Breast Cancer 
Group (DBCG) standard since 1982. Results from the UK and 
Canada stimulated a renewed interest in hypofractionation, 
and the non-inferiority DBCG HYPO trial was initiated. The 
hypothesis was that 40 Gy/15 fr (2.67 Gy/fr, 3 weeks) does 
not result in more grade 2-3 breast induration than 50 Gy/25 
fr (2.0 Gy/fr, 5 weeks) 3 years post RT. 
 
Materials and Methods: From 2009-2014 1868 patients >40 
years operated with breast conservation for early pT1-2 pN0-
1(mic) BC (n=1617) or DCIS (n=251) were enrolled irrespective 
of breast size, systemic therapy and boost, and randomized 
50 Gy/25 fr vs. 40Gy/15 fr. Strata were institution, breast 
size (≤ 600 ml vs. > 600 ml), systemic therapy and boost. The 
primary endpoint was grade 2-3 induration 3 years post RT, 
secondary endpoints were other normal tissue responses, 
genetic risk profile for RT-induced fibrosis and recurrences. 
ClinicalTrial NCT00909818. 
 
Results: 942 pts (50.4%) were assigned to the 50 Gy group 
and 926 (49.6%) to the 40 Gy group. Median age was 59 years 
(range 39-83). Median follow up was 3 years. The analysis was 
by intention to treat. Results are actuarial 3 year rates using 
morbidity in 1801 pts 1 yr post RT as baseline. 1086 pts (60%) 
had 3 year scores of morbidity and the rate of grade 2-3 
induration was 12.2%±1%. Grade 2-3 induration was seen in 
the 50 Gy group in 119 out of 904 pts with the rate 
14.2%±1.4%, and in the 40 Gy group in 97 out of 897 pts, the 
rate being 10.1% ±1%, representing a HR 1.27 (95% CI 0.97-
1.66), p=0.08. 859 pts (48%) had small breasts with a rate of 
grade 2-3 induration of 9.8%±1% compared to 14.3%±1% 
among 942 pts with large breasts, HR 1.56, (95% CI 1.18-
2.05), p=0.001. Among the 653 pts (36%) treated with 
chemotherapy (CT) the rate of grade 2-3 induration was 
12.4%±1%, whilst in the 1148 pts with no CT the rate was 
11.8%±2%, HR 0.98 (95% CI 0.74-1.30), p=0.90. In 423 pts 
(23%) treated with sequential boost (10-16 Gy/5-8 fr) the 
rate of grade 2-3 induration was 12.4%±1% compared to 
12.1%±1% among 1378 pts with no boost, HR 0.93 (95% CI 
0.67-1.29), p=0.65. Multivariate analysis using grade 2-3 
induration at 3 yr as endpoint and including 
hypofractionation, breast size, chemotherapy and boost 
identified large breast size as the only independent risk 
factor. Overall the 3 yr risk of loco-regional recurrence was 
0.3%±0.1%. In the 50Gy / 40 Gy group loco-regional 
recurrence was reported in 2 pts / 4 pts, distant failure 4 pts 
/ 3 pts, new contralateral cancer or DCIS 2 pts / 3 pts.  
 
Conclusion: Moderately hypofractionated whole breast 
irradiation in early node-negative BC or DCIS does not result 
in more grade 2-3 induration compared to normofractionated 
therapy. Large breast size is an independent risk factor for 
developing induration. The 3 yr loco-regional recurrence risk 
is very low. 
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Purpose or Objective: We report preliminary results from a 
Bayescian randomized trial of IMRT vs. PSPT , both given with 
concurrent chemotherapy, for locally advanced (stage II-IIIB) 
NSCLC. The purpose of the trial was to assess and compare 
the incidence and time to development of treatment failure 
defined as (1) grade ≥3 pneumonitis or (2) local failure, 
whichever occurred first in 12 month. 
 
Materials and Methods: The sample size for this trial (n=150) 
was based on the assumption that incidence would be log-
normally distributed and that IMRT would produce event 
rates of 30% at 6 mo and 40% at 12 mo, and PSPT would 
reduce the event rate by 10%. The Bayescian design was 
chosen so that more patients will be randomly allocated to 
the more effective of the two treatments. All patients must 
have been candidates for concurent chemoradiation, and all 
underwent 4D CT-based treatment planning. An IMRT and a 
PSPT plan were created for each patient. Patients were 
eligible for randomization only if both plans satisfied normal 
tissue constraints at the same prescription dose (74 Gy (RBE) 
if achievable , otherwise 66 Gy (RBE), where RBE is 1 for 
photons and 1.1 for protons) 
 
Results: Total 147 patients who were randomized to IMRT 
(n=90) or PSPT (n=57) and treated according to randomization 
were included for this analysis. Demographic characteristics 
were well balanced between the two arms. The GTV and PTV 
volumes were bigger in the PSPT arm though the difference 
was not statisically significant. More patients in PSPT arm 
received higher tumor dose. Patients in PSPT arm had larger 
volume of the lung receiving ≥30 -80 Gy (RBE) compared with 
IMRT patients, presumably due to the larger target volume 
and 3D nature of PSPT. The incidence of protocol failure at 
12 month were 20.7%, 15.6%, and 24.6% in all, in IMRT, and in 
PSPT patients, respectively. The median failure free survival 
times were 67.6, 67.6, and 69. 8 months in all, in IMRT, and 
in PSPT patients, respectively. Total of 12 patients developed 
grade ≥3 or higher RP, 6 in each arm. Two of the 6 patients 
had grade 5 RP in IMRT arm. The incidences of grade ≥3 RP 
were 8.7%, 7.2%, and 11.0% in all, in IMRT, and in PSPT 
patients, respectively. 
 
Conclusion: Considerably fewer events occurred in the 
evaulable randomized patients than were expected from 
historical experience. No statistical differences were found 
between IMRT vs. PSPT in the incidence of treatment failure, 
grade ≥3 pneumonitis, or local failure. Future analyses will 
involve comparing data from CT and PET images, blood 
samples and symptoms and their correlations with dose 
distributions to clarify factors affecting outcomes and to 
determine how physical and biological uncertainties affect 
proton dose distributions. *Supported in part by NCI grants 
P01 CA021230 and U19 CA021239. 
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Purpose or Objective: The role of prophylactic cranial 
irradiation (PCI) in limited disease (LD) small-cell lung cancer 
(SCLC) has proven to significantly decrease the incidence of 
